Key result
Acetazolamide emerges as a potential therapy to slow vascular calcification by lowering pH and phosphate.
Why the study?
Vascular calcification is a recognized source of morbidity in mid-age and elderly subjects, and its development is inhibited by acidosis, suggesting a potential role for acetazolamide.
Does acetazolamide inhibit the progression of atheromatous calcification in mid-age and elderly subjects?
Does acetazolamide inhibit the progression of atheromatous calcification in mid-age and elderly subjects?
This paper proposes a novel hypothesis that acetazolamide could be repurposed to retard vascular calcification by inducing mild metabolic acidosis and phosphate loss.
Answers are grounded in this paper and cite their sources.
No evidence supports acetazolamide for vascular calcification; hypothesis-generating and requires prospective trials.
BackgroundVascular calcification is a recognised source of morbidity among mid-age and elderly subjects.Its development follows classical mineralisation pathways, inhibited by acidosis. AimsTo examine the argument for using acetazolamide to retard vascular calcification. ResultsThe final mechanism of tissue mineralization involves three processes, all of which are highly pH dependent.Calcium interacts with phosphate in its trivalent form, but this step is inhibited by pyrophosphate, the substrate for alkaline phosphatase.Separately, matrix vesicles create nucleation sites and indirectly disrupt vascular smooth muscle cells.Metabolic acidosis acts at every point to delay mineralization.The diuretic acetazolamide creates a sustained mild acidosis and phosphate loss and, though usually ineffective in the experimental model, has been used with success in certain clinical conditions. ConclusionWe suggest that acetazolamide, well studied and tolerated, could be trialled in selected subjects to offset the progression of vascular calcification, through its dual action of lowering tissue pH and phosphate concentration.
No takes yet. Share an insight, caveat, or question.
Malcolm Cochran (2019) conducted a review in Vascular calcification. Acetazolamide was evaluated. The authors hypothesize that acetazolamide could be trialled to offset the progression of vascular calcification through its dual action of lowering tissue pH and phosphate concentration.
Synapse has enriched 10 related papers. Consider them for comparative context: